AGIO vs BRVE: stock comparison and AI forecast
Agios Pharmaceuticals, Inc. (AGIO) and Braveheart Bio, Inc. (BRVE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AGIO Agios Pharmaceuticals, Inc.
- Price
- $30.55 +9.1% · 6M
- Market Cap
- $1.82B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
BRVE Braveheart Bio, Inc.
- Price
- $21.51 -26.9% · 6M
- Market Cap
- $1.76B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AGIO and BRVE have similar market capitalizations ($1.82B and $1.76B).
- Over the last six months AGIO returned +9.1% and BRVE -26.9%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AGIO | BRVE |
|---|---|---|
| Market Cap | $1.82B | $1.76B |
| P/B Ratio | 1.78x | – |
| EPS | $-7.02 | – |
| Book Value/Share | $17.19 | – |
| Revenue/Share | $1.30 | – |
| FCF/Share | $-6.12 | – |
Profitability & Margins
| Metric | AGIO | BRVE |
|---|---|---|
| ROE | -40.1% | – |
| ROA | -37.1% | – |
| ROIC | -44.2% | – |
| Gross Margin | 91.5% | – |
| Operating Margin | -591.6% | – |
| Net Margin | -530.1% | – |
| EBT Margin | -516.4% | – |
| Tax Rate | 0.6% | – |
Financial Health
| Metric | AGIO | BRVE |
|---|---|---|
| Current Ratio | 10.22x | 13.63x |
| Quick Ratio | 9.71x | – |
| D/E Ratio | 0.08x | – |
| Financial Leverage | 1.08x | – |
| Working Capital | $647M | $114M |
Cash Flow
| Metric | AGIO | BRVE |
|---|---|---|
| Operating Cash Flow | -$361M | – |
| Free Cash Flow | -$365M | – |
| Capital Spending | -$5M | – |
| FCF/Sales | -470.7% | – |
| CapEx/Sales | 6.0% | – |
Operational Efficiency
| Metric | AGIO | BRVE |
|---|---|---|
| Asset Turnover | 0.07x | – |
| Inventory Turnover | 0.2x | – |
| Fixed Assets Turnover | 7.8x | – |
| Days Inventory | 1658 days | – |
| Payables Period | 758 days | – |
Income Statement
| Metric | AGIO | BRVE |
|---|---|---|
| Total Revenue | $78M | – |
| Operating Income | -$459M | – |
| Net Income | -$411M | – |
| R&D Expense | $357M | – |
| SG&A Expense | $193M | – |
| Cost of Goods Sold | $8M | – |
Dividend & Shareholder Information
| Metric | AGIO | BRVE |
|---|---|---|
| Shares Outstanding | 60M | 82M |
| Net Income Growth | -163.3% | – |
| EPS Growth | -162.1% | – |
AGIO vs BRVE: stock comparison and AI forecast
Which is bigger, AGIO or BRVE?
AGIO and BRVE have similar market capitalizations ($1.82B and $1.76B).
Which stock performed better over the last six months, AGIO or BRVE?
Over the last six months AGIO returned +9.1% and BRVE -26.9%.
Which one does Intratio's AI model rank higher, AGIO or BRVE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.